We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
76
Crinetics Pharmaceuticals
CRNX
$8.88B
$8.7M 0.03%
616,520
+314,200
+104% +$4.38M
VXRT
77
DELISTED
Vaxart
VXRT
$7.99M 0.03%
1,398,795
-167,326
-11% -$1.06M
CABA icon
78
Cabaletta Bio
CABA
$427M
$7.94M 0.03%
636,363
– –
HOOK
79
DELISTED
HOOKIPA Pharma
HOOK
$7.77M 0.03%
70,048
– –
SYRS
80
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.49M 0.03%
69,017
– –
DNLI icon
81
Denali Therapeutics
DNLI
$3.79B
$7.43M 0.03%
88,738
-10,662
-11% -$645K
KRTX
82
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$7.11M 0.03%
69,966
-7,810
-10% -$724K
AUTL
83
Autolus Therapeutics
AUTL
$389M
$6.99M 0.03%
782,183
+320,859
+70% +$3.42M
HRMY icon
84
Harmony Biosciences
HRMY
$2.08B
$6.51M 0.02%
180,000
-220,000
-55% -$8.88M
GTH
85
DELISTED
Genetron Holdings Limited ADS
GTH
$6.37M 0.02%
151,769
+118,436
+355% +$4.29M
NTLA icon
86
Intellia Therapeutics
NTLA
$1.51B
$6.05M 0.02%
111,296
-10,942
-9% -$397K
PASG icon
87
Passage Bio
PASG
$14.5M
$6.02M 0.02%
11,768
-1,285
-10% -$515K
REPL icon
88
Replimune Group
REPL
$454M
$5.86M 0.02%
153,512
-53,074
-26% -$2.21M
ITOS
89
DELISTED
iTeos Therapeutics
ITOS
$5.08M 0.02%
150,346
-17,216
-10% -$456K
TARA icon
90
Protara Therapeutics
TARA
$214M
$4.83M 0.02%
199,671
– –
BNR
91
Burning Rock Biotech
BNR
$93M
$4.83M 0.02%
20,913
-2,817
-12% -$756K
GOSS icon
92
Gossamer Bio
GOSS
$101M
$4.65M 0.02%
+480,729
New +$4.74M
MGNX icon
93
MacroGenics
MGNX
$233M
$4.59M 0.02%
+200,679
New +$4.62M
TCDA
94
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.44M 0.02%
+629,300
New +$4.83M
IFRX icon
95
InflaRx
IFRX
$243M
$4.31M 0.02%
856,228
-151,331
-15% -$681K
ALEC icon
96
Alector
ALEC
$169M
$3.62M 0.01%
239,228
-26,372
-10% -$328K
LOGC
97
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$3.44M 0.01%
+451,478
New +$3.02M
TCRR
98
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.43M 0.01%
110,888
-11,644
-10% -$294K
CNST
99
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.3M 0.01%
114,735
-18,598
-14% -$468K
LEGN icon
100
Legend Biotech
LEGN
$3.65B
$3.26M 0.01%
115,626
-12,574
-10% -$362K
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.